Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.
NEW YORK/FRANKFURT (Reuters) – Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback